
    
      A Phase 2 Trial of AU-011 Via Suprachoroidal Administration With a Dose Escalation Phase
      (Open-label, Ascending Single and Repeat Dose) and a Randomized, Masked Dose Expansion Phase
      Designed to Evaluate the Safety and Efficacy of AU-011 in Subjects With Primary Indeterminate
      Lesions and Small Choroidal Melanoma.
    
  